



Brazil - HTA Country/Area Profile



Institutions & Governance

| Question | Options | Response |
|--|-------------------|----------|
| Has a systematic process to support healthcare decision-making? | National Level | Yes |
| | Subnational Level | Yes |
| Do you refer to this as HTA? | | Yes |
| Existence of standard methodology or process guideline? | | Yes |
| Legislative and/or regulatory requirement to consider HTA results in health benefit package decisions? | | Yes |

| Question | Options | Response |
|--|--|----------|
| Functions for which decision-making information is gathered? | Clinical practice guidelines | Yes |
| | Planning and budgeting | Yes |
| | Pricing/pricing negotiations of medical technologies | Yes |
| | Indicators of quality of care | No |
| | Objectives for pay-for-performance schemes | No |
| | Design of Health Benefit Packages | Yes |
| | Public Procurement of Medicines | Yes |
| | Protocols for public health programmes | No |
| Other | N/R | |

| Organizations responsible for assessment, appraisal, and recommendation | Pharmaceutical/ Medicines | Medical Procedures | Medical Devices | Diagnostic Tests | Population Level Health Interventions |
|---|---------------------------|--------------------|-------------------|-------------------|---------------------------------------|
| Appraisal | CONITEC / REBRATS | CONITEC / REBRATS | CONITEC / REBRATS | CONITEC / REBRATS | CONITEC / REBRATS |
| Assessment | CONITEC / REBRATS | CONITEC / REBRATS | CONITEC / REBRATS | CONITEC / REBRATS | CONITEC / REBRATS |
| Recommendation | CONITEC / REBRATS | CONITEC / REBRATS | CONITEC / REBRATS | CONITEC / REBRATS | CONITEC / REBRATS |

| Question | Options | Response | Question | Response |
|--|---|----------|---|----------|
| Who nominates or selects interventions to be reviewed? | Scientific Committee of the HTA or decision-making body | Yes | Mechanism for translation or contextualization of evidence? | No |
| | Executive Board of the HTA or decision-making body | Yes | Is there a provision for rapid assessment, appraisal and recommendation in a non-emergency context? | Yes |
| | Director of the HTA or decision-making body | Yes | Is there a provision for rapid assessment, appraisal and recommendation in an emergency context? | N/R |
| | Department/Ministry of Health | Yes | Do you assess impact? | N/R |
| | National Health Service | Yes | | |
| | Patient Organizations | Yes | | |
| | Civil Society | Yes | | |
| | Other | N/R | | |



Available Resources

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries



Brazil - HTA Country/Area Profile



| Question | Response |
|---|----------|
| How many professional staff (FTE) are involved in the HTA body? | 21 to 50 |
| Allocated public sector budget? | Yes |

| Question | Response |
|---|----------|
| Are any resources received through private funding? | N/R |
| If so, what percentage? | N/A |



Assessments

| Question | Response |
|---|----------|
| How long does the assessment process take on average? | N/R |
| In the last 12 months, approximately how many assessments were performed? | 70 |



Appraisals

| Question | Response |
|--|----------|
| Are there national guidelines for the preparation of economic evaluations? | Yes |
| Do you have a database of health technology costs or prices? | Yes |
| Is there an officially endorsed cost-effectiveness threshold? | N/R |
| If so, what is it? | N/A |
| Are stakeholders not represented in the appraisal body invited to react/comment? | Yes |
| Are members of the appraisal body required to provide a declaration of conflict of interest? | Yes |



Recommendations

| Question | Response |
|---|----------|
| Is there a possibility to appeal against the decision? | N/A |
| Is there a separate entity responsible for recommendation after the appraisal process has been conducted? | No |

| | Assessment reports | Minutes of the meetings | Rationale for the decision | Recommendations (or decisions where relevant) | Other, please specify | No outputs from the recommendation process are published |
|--|--------------------|-------------------------|----------------------------|---|-----------------------|--|
| Are the following published and readily available? | Yes | Yes | Yes | Yes | No | No |



Barriers

| Question | Ranking | Response |
|-----------------|---------|---|
| Barriers to Use | Rank 1 | Awareness/Advocacy of the importance of HTA |
| | Rank 2 | Qualified human resources |
| | Rank 3 | N/R |
| | Rank 4 | N/R |
| | Rank 5 | N/R |
| | Rank 6 | N/R |

| Question | Ranking | Response |
|-----------------------------------|---------|---------------------------|
| Barriers to Production Capability | Rank 1 | Dedicated human resources |
| | Rank 2 | N/R |
| | Rank 3 | N/R |
| | Rank 4 | N/R |
| | Rank 5 | N/R |

1. These results come from the 2020/2021 WHO Global Survey on HTA and Health Benefit Packages.

2. "N/A" stands for 'not applicable' and "N/R" stands 'no reply'.

Disclaimer: The term "national" should be understood to refer to countries and areas. The designations employed and the presentation of the material in this platform do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries